SCHEMBL24718232

SCHEMBL24718232

CCOC(=O)c1ccc(N)c(C)c1C(=O)OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
HSD17B10 Q99714 4/20 0.53
KDM4E B2RXH2 3/20 0.50
TSHR P16473 2/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA7 P43166 3/20 0.44
CA9 Q16790 3/20 0.44
CA14 Q9ULX7 3/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
GAA P10253 4/20 0.43
HPGD P15428 3/20 0.43
CDC25B P30305 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772841 0.89 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL7443982 0.83 TSHR (0.49) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL27092907 0.82 ALDH1A1 (0.45) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL55681 0.82 ALDH1A1 (0.61) ALDH1A1HSD17B10TSHRMAPTMEN1
SCHEMBL24717740 0.81 TSHR (0.47) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL7438131 0.80 KDM4E (0.43) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL9029993 0.80 KDM4E (0.43) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL30055825 0.79 ALDH1A1 (0.49) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL7499227 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4ETSHRMAPT
SCHEMBL26126976 0.78 TSHR (0.50) ALDH1A1HSD17B10KDM4ETSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025041076-A1 BICYCLIC COMPOUNDS AS CDK INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-02-27 WO disclosed
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-10-03 US disclosed
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-21 US disclosed
EP-4323352-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-02-21 EP disclosed
CN-117279910-A Modulators of BCL6 proteolysis and related methods of use 阿尔维纳斯运营股份有限公司 2023-12-22 CN disclosed
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 ALDH1A1 3862/4885HSD17B10 3030/4885KDM4E 665/4885
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 ALDH1A1 3862/4885HSD17B10 3030/4885KDM4E 665/4885
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 ALDH1A1 3862/4885HSD17B10 3030/4885KDM4E 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.